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Abstract To study the currently available data of recur-
rence rates of functioning and nonfunctioning pituitary
adenomas following surgical cure and to analyze associ-
ated predisposing factors, which are not well established.
A systematic literature search was conducted using Med-
line, Embase, Web of Science and the Cochran Library for
studies reporting data on recurrence of pituitary adenoma
after surgery, in nonfunctioning adenoma (NF), prolacti-
noma (PRL) acromegaly (ACRO) and Cushing’s disease
(CUSH). Of 557 initially retrieved potential relevant
studies 143 were selected. Recurrence in NFA was deﬁned
as reappearance of tumor on MRI or CT. Increase of hor-
mone levels above normal limits as set by the authors after
initial remission was used to indicate recurrence in the
functioning tumor types. Remission percentage was lowest
in NFA compared with other tumor types (P\0.001).
Surgery-related hypopituitarism was more frequent in
CUSH than in the other tumors (P\0.001). Recurrence,
expressed as percentage of the cured population or as ratio
of recurrence and total patient years of follow-up was
highest in PRL (P\0.001). The remission percentage did
not improve over 3 decades of publications, but there was a
modest decrease in recurrence rate (P = 0.04). Recur-
rences peaked between 1 and 5 years after surgery. Most of
the studies with a sufﬁcient number of recurrences did not
apply multivariate statistics, and mentioned at best asso-
ciated factors. Age, gender, tumor size and invasion were
generally unrelated to recurrence. For functioning adeno-
mas a low postoperative hormone concentration was a
prognostically favorable factor. In NFA no speciﬁc factor
predicted recurrence. Recurrence rate differs between
pituitary adenomas, being highest in patients with prolac-
tinoma, with the highest incidence of recurrence between 1
and 5 years after surgery in all adenomas. Patients with
NFA have a lower chance of remission than patients with
functioning adenomas. The postoperative basal hormone
level is the most important predictor for recurrence in
functioning adenomas, while in NFA no single convincing
factor could be identiﬁed.
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Introduction
Over the last four decades the preferred treatment of choice
of pituitary adenomas has been transsphenoidal surgery,
although primary medical treatment is currently used in
most patients with prolactinoma and in selected patients
with acromegaly [1–4]. The obvious advantage of surgery
is the quick relief of signs and symptoms, and the arrest of
permanent damage to organ systems caused by the hor-
monal excess. Recurrence of a pituitary adenoma after
apparent cure is well recognized, but the clinical predictive
factors associated with relapse have not been studied sys-
tematically and compared between different types of ade-
nomas. The purpose of this study is to present a systematic
review and meta-analysis of publications spanning the last
three decades of pituitary surgery and reporting remission
and recurrence of pituitary adenomas during long-term
follow-up studies. Particular attention was given to clinical
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DOI 10.1007/s11102-011-0347-7factors predicting recurrence of an adenoma, also when this
was not the primary goal of the reported study. Many
factors may inﬂuence the proliferation of pituitary adeno-
mas, such as angiogenesis, apoptosis, growth factors,
oncogenes, tumor suppressor genes, and hormone receptors
[5, 6]. However, we did not include reports investigating
the association of biochemical tumor factors with the risk
of recurrence of the adenoma, since the majority of these
reports was not based on unselected patient groups.
Study design
Search strategy
The following databases for studies addressing the recur-
rence of pituitary adenomas after transsphenoidal surgery
weresearched:PubMed,CochraneLibrary,WebofScience,
EMBASE, CINAHL, PsycINFO, Academic Search Premier
and Science Direct. The ﬁnal search was performed on
August 1, 2011. We devised a search strategy for the men-
tioned databases with the help of a trained clinical librarian
focusing on pituitary adenomas, treatment and recurrence
after treatment. All relevant keyword variations were used,
including free text words. The references of the relevant
articleswerecheckedforadditionalarticles.Originalarticles
in the English, German, French and Dutch languages were
included. Studies were eligible for inclusion in this review
when they fulﬁlled the following criteria: more than 20
patients included with a mean follow-up period of at least
1 year. Studies were excluded when restricted to elderly
patients ([80 years) or adolescents and children, when
patients underwent repeat pituitary surgery, pituitary irra-
diation, transcranial surgery, or in the presence of rare
pituitary adenomas e.g. TSH secreting adenomas or func-
tioning gonadotropinomas, hereditary tumors, e.g. MEN I
syndrome or when regrowth and recurrence of nonfunc-
tioning adenomas were considered as equivalent entities. In
case of (partial) duplication of cohorts, the paper with the
longest duration of follow-up was included in the review.
Data review and analysis
Initialselectionofstudiesbytitleandabstractwasperformed
byonereviewer(FR)andthesestudieswereretrievedforfull
assessment. Three reviewers independently evaluated all
studies and disagreement was resolved by consensus. The
retrieved documents were screened and evaluated with a
question list of 60 different items, which was then used to
construct the database. The list included bibliographical
details, background of the study, study design, recruitment
period,inclusionandexclusioncriteria,detailsondiagnosis,
type of hormone assays used, normal test values, and
eventual preoperative medical treatment. Furthermore we
noted the number of included patients, the total number
undergoing surgery, the number lost to follow-up, deaths,
duration of follow-up, surgical details, criteria of cure,
details of CT and MRI investigations, immediate postoper-
ative results, surgically induced hypopituitarism, improved
hypopituitarism, used methods for diagnosis of hypopitu-
itarism, number of recurrences in time, histology of the
tumor including immunohistochemistry, presence of inva-
siveness, and potential tumor growth factors. Finally we
looked for recurrence-associated factors, e.g. age, gender,
tumor size, postoperative hormone concentrations, inva-
siveness(macroscopicandmicroscopic),surgicaltechnique,
surgical center, biological tumor factors and the used
statistical analyses.
Statistical analysis
Primary outcomes of this review were short-term remission
aftersinglesurgeryandinducedpituitaryfailure.Tothisend
we used the criteria set by the authors of each publication,
either biochemical or in case of nonfunctioning adenoma
(NFA) CT and/or MRI evaluation. The other main primary
outcome was the incidence of recurrence of the adenoma
afterclinicalcure,asreportedbytheauthors.IncaseofNFA
the postoperative CTorMRIshould show notumorremnant
and studies using regrowth of a tumor remnant were exclu-
ded, unless a distinction between the two cases was made
clearly. In addition we carefully evaluated clinical factors
associated with recurrence were carefully evaluated. Statis-
tical comparison between groups was done with ANOVA,
with selected post-hoc contrasts. Regression analysis was
usedfortime-dependentobservations.Pvalues\0.05were
considered signiﬁcant.
Results
The initial search resulted in a total of 1,663 publications.
Of these 1,106 were excluded on the basis of title and
abstract. The remaining 557 articles were assessed for
inclusion in this study, and a further 427 articles were
excluded on the basis of reading the full text, leaving 130
studies which fulﬁlled the criteria of our search. Thirteen
papers were identiﬁed from other sources, mainly from
references cited in the read papers. Details of the search
strategy with the distribution along the 4 main groups of
pituitary adenomas are shown in Fig. 1.
Short-term results of pituitary surgery
Thirty studies reported results on surgery in prolactinoma
patients [7–36], 31 studies in NFA [9, 37–65], 32 studies in
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123acromegaly [12, 18, 19, 29, 49, 66–91] and 50 studies in
Cushing’s disease [12, 19, 29, 92–138]. The distribution of
these reports across the years is shown in Fig. 2.
The number of patients treated with a single surgical
procedure for prolactinoma, NFA, acromegaly and Cush-
ing’sdiseasewererespectively3,152,5,022,3,548and5,787
patients. The absolute number of remission in these groups
were 1,949, 2,232, 2,162 and 4,207 patients, respectively,
with an overall remission percentage of respectively 61.7,
44.4, 60.9 and 72.7% (see Table 1). The remission percent-
age, as reported in the papers, is shown in Fig. 3. The mean
remission values and (ranges) were 68.8% (27–100) in pro-
lactinoma, 47.3% (3–92) in NFA, 61.2% (37–88) in acro-
megaly, and 71.3% (41–98) in Cushing’s disease. The
surgicalresultsarealsoshownasboxplotsinFig. 3.Patients
with NFA had a lower remission percentage compared with
the other patient groups (P\0.001). Patients with Cush-
ing’sdiseasehadahigherremissionpercentagethanpatients
with acromegaly (P = 0.01). The overall surgical results
with respect to postoperative normalization according to
criteriaset bythe authorsdidnotshow animprovement over
the last 3 decades (publication year coefﬁcient -0.18 ±
0.17, P = 0.29, see Fig. 4).
The incidence of new, surgery-related pituitary deﬁ-
ciencies is displayed in Fig. 5. It should be noted, however,
that only 55% of the studies reported data on surgery-
related pituitary deﬁciencies, as shown on the ordinate of
the ﬁgure. The incidence of pituitary insufﬁciency was
highest in patients with Cushing’s disease (P\0.0001),
but the incidence of (new) pituitary insufﬁciency in NFA
patients was not higher than in patients with prolactinoma
or acromegaly (P = 0.22).
Results of long-term follow-up
The absolute number of patients in remission after surgery
who were includedin follow-upstudies isshowninTable 1.
This table also shows the total durationof follow-upin years
and the number of recurrences. The mean reported years of
follow-up was 4.90 ± 0.57 in prolactinoma, 5.13 ± 0.24 in
NFA, 6.36 ± 0.58 in acromegaly and 4.91 ± 0.34 in
Cushing’s disease. The follow-up was longer in acromegaly
than in the other groups (P\0.01). The percentage tumor
recurrence as mentioned in the papers or calculated from
available data is shown in Fig. 6. The recurrence incidence
was lowest in patients with acromegaly (P\0.0001). Pro-
lactinoma patients had a higher recurrence incidence than
patients with acromegaly and Cushing’s disease (P\
0.0001), but there was no difference between patients with
NFA and prolactinoma (P = 0.17).
Studies with a different follow-up period could be
compared when recurrence was expressed as number of
recurrences per total years at risk. The overall recurrence
rate, related to follow-up years, could be calculated from
the data shown in Table 1. This was respectively for the 4
groups 0.034, 0.022, 0.007 and 0.023 patients/years. The
recurrence rate for the 4 groups, as deﬁned above, is shown
in Fig. 7. Patients with acromegaly had a better long-term
outcome than patients in the other 3 groups (P\0.0001),
while patients with a prolactinoma had a higher recurrence
rate than patients in the other groups (P\0.001). There
was no difference between NFA and prolactinoma patients
(P = 0.09).
No change in recurrence incidence was observed over 3
decades of publications (P = 0.51), although the recur-
rence rate showed a modest improvement with time
(coefﬁcient -0.0007 ± 0.0003, P = 0.04, see Fig. 8). The
 1663 potential 
relevant studies
 1106 excluded
(Title & abstract)
  557 papers for
detailed assesment
427 papers excluded
   on basis of text
130 studies for
final assesment
PRL 28 NFA 31 ACRO 25 CUSH 46
PRL 30 NFA 31 ACRO 32 CUSH 50
143 studies included
13 added from
other sources
Fig. 1 Flow chart of the study assessment and used criteria. Used
abbreviations are PRL: prolactinoma, NFA: nonfunctioning adenoma,
ACRO: acromegaly and CUSH: M. Cushing
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Fig. 2 Distribution of the publications on pituitary adenomas over 3
decades of transsphenoidal pituitary surgery
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123majority of recurrences occurred between 1 and 5 years
after surgery, although patients with acromegaly and NFA
also displayed a signiﬁcant number of recurrences between
5 and 10 years (Fig. 9). These data were based on papers
that provided details on recurrence during follow-up (77%
of the prolactinoma papers, 71% of NFA papers, 72% of
acromegaly papers and 70% of papers on Cushing’s
disease).
Table 1 Absolute number of patients, remission, recurrence and follow-up period
PRL NFA ACRO CUSH
Number of patients 3,152 5,022 3,548 5,787
Number of patients in remission 1,949 2,232 2,162 4,207
Number of patients in remission in follow-up 1,771 2,065 1,980 4,206
Total years of follow-up in patients in remission 9,861 10,411 14,082 21,229
Number of recurrences 339 236 98 491
PRL prolactinoma, NFA nonfunctioning adenoma, ACRO acromegaly, Cush Cushing’s disease
Remission Percentage
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ANOVA: P<0.001
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ACRO vs CUSH: P=0.01
ACRO vs PRL: NS
Fig. 3 Box-plots of the remission percentage after pituitary surgery
in patients with prolactinoma, nonfunctioning adenoma, acromegaly
and Cushing’s disease
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Fig. 4 Regression analysis of tumor type, year of publication and
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Fig. 5 The incidence of new hypopituitarism caused by pituitary
surgery. The numbers between parentheses refer to the number of
studies reporting hypopituitarism and the total number of manuscripts
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Fig. 6 Box-plots of the recurrence percentage during follow-up
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123There was a weak linear correlation between recurrence
percentage and remission percentage (R
2 = 0.032, P =
0.03). Short-term and long-term surgical results did not
differ between European and American studies.
Prognostic factors for adenoma recurrence
The search of prognostic factors involved in pituitary
adenoma recurrence was hampered by several factors.
Some studies reported zero recurrences during follow-up,
thus logically excluding any prognostic factor. This was the
case in 6 studies in NFA [37, 49, 52, 56, 60, 139], 1 study
on prolactinoma [49], 12 studies in acromegaly [12, 29, 49,
68, 73, 76, 79, 89, 90, 140–142] and 3 studies in Cushing’s
disease [118, 120, 136]. Studies with a low absolute
number of recurrences mostly did not generally provide
clinical details and ﬁnally multivariate analysis was rarely
performed when a sufﬁcient number of recurrences were
present. We were therefore obliged to apply a simpliﬁed
approach and we selected studies where one or more fac-
tors, such as age, gender, tumor size, invasion etc., were
considered to be associated with recurrence or excluded as
a signiﬁcant factor for it, and scored these as ‘yes’ and ‘no’,
respectively, as shown in Fig. 10, with the bars represent-
ing the number of studies. The ﬁgures at the end of the bars
are the absolute number of patients with relapse, and the
total years of follow-up in patients at risk.
In NFA, age [40, 44, 51, 54, 55, 57, 61, 63, 143], gender
[40, 44, 45, 51, 54, 57, 61, 63, 143], tumor size [40, 44, 51,
54, 55, 57, 61, 63, 143], and tumor invasion had prognostic
signiﬁcance in some studies[40, 41, 64], but not in others
[51, 54, 57, 63]. Histology was a predictor in some studies
[40, 43, 47, 57, 58], but not in others [54, 61, 64, 143].
In prolactinoma, age [15, 21, 24, 27, 144], gender [21,
23, 24, 27] and macroscopic and microscopic tumor inva-
sion were not signiﬁcant factors for recurrence [15, 21, 24,
26, 27]. Tumor size was not a convincing factor [7, 8, 10,
15, 30, 34, 144] while a low basal postoperative PRL
concentration (below 10 or 6 lg/L thus much lower than
the upper normal basal PRL level of 20 or 22 lg/L) [7, 15,
23, 24, 28, 30, 34, 144] and normalization of the TRH test
were favorable clinical factors associated with permanent
cure [10, 21, 30]. In acromegaly, tumor recurrence was
unlikely in patients with a low postoperative GH concen-
tration [69, 87, 145, 146], a low glucose-suppressed GH
concentration [147, 148], or with normalization of the
paradoxical GH increase after TRH infusion [149]. Tumor
size [66, 69, 71, 81, 145, 146] and invasion [66, 84] were
not deﬁnite prognostic factors in acromegaly. In Cushing’s
disease, age [98, 117, 134, 150], gender [117, 134,
150],tumor size [95, 98, 111, 117, 121, 132, 134, 150] and
macroscopic tumor invasion [95, 98, 117, 134] were not
prognostic factors of recurrence. Microscopic tumor inva-
sion [29, 92, 117, 126, 134], as well as postoperative
dexamethasone tests [93, 95, 96, 98, 114, 134] were
undetermined factors. However, a signiﬁcant positive and
favorable factor was a low basal postoperative cortisol
concentration in more studies [19, 29, 93, 97, 99, 104, 105,
107, 109, 112–114, 116, 121–123, 127, 129, 130, 133,
Recurrence Rate during Follow-Up
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Fig. 7 Box-plots of the recurrence rate in patients treated by
transsphenoidal surgery (ratio of the number of recurrences and years
of follow-up in patients at risk) Note that the lowest recurrence rate
was found in patients with acromegaly: P value versus Cushing’s
disease P = 0.013, versus NFA P = 0.003 and versus prolactinoma
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123151], than in those which did not conﬁrm this ﬁnding
[92, 95, 98, 117, 134, 138].
Discussion
An important outcome of surgery of pituitary adenomas is
the immediate cure rate and the impact on normal pituitary
function. In our study we restricted the analysis to studies
that reported both short-term and long-term results of
surgery in unselected patient series. Our data analyses
demonstrate that patients with NFA have a lower chance of
remission, which is not too surprising, because many
patients are not diagnosed until the tumor is large resulting
in compression of the optic chiasm with generally sub-
stantial supra- and para-sellar extension, making curative
surgery less feasible than in (functioning) adenomas
restricted to the sella turcica. Indeed, many studies in
acromegaly, prolactinoma and Cushing’s disease, have
stressed the difference in remission percentage between
patients with a microadenoma and those with a macroad-
enoma [34, 80, 152, 153]. The overall (initial) remission in
patients with prolactinoma is comparable with the remis-
sion achieved in patients with acromegaly and Cushing’s
disease, suggesting that the tumor type per se does not
inﬂuence outcome.
Recurrence of a functioning adenoma was based on the
reappearance of clinical signs and symptoms, conﬁrmed by
biochemical tests, as used by the authors. In order to allow
a fair comparison with the other adenoma types, in NFA
recurrence was deﬁned as reappearance of an adenoma,
thus excluding patients with growth of a tumor remnant,
possible. For this review recurrence was either expressed as
percentage of patients who could be followed-up and thus
at risk for recurrence (thus controlling for deaths and other
causes of follow-up failure) and as recurrence rate. The
latter expression is the ratio of number of recurrences and
total years of patients at risk, thus (partially) eliminating
differences in follow-up time between studies. This study
shows that patients with acromegaly had fewer recurrences
than patients with other pituitary adenomas, both expressed
as percentage and as recurrence rate. In contrast, patients
with prolactinoma had a higher recurrence percentage and
rate than patients with acromegaly or Cushing’s disease. At
present, this behavior of prolactinoma is largely unex-
plained, but may be related to deﬁnition of cure, or to more
frequent microscopic tumor inﬁltration into normal pitui-
tary tissue, which is not removed at surgery.
Another interesting point emerging from this study is
that the remission percentage of transsphenoidal surgery
did not improve over the last three decades. The majority
of papers ([95%) which were included in this review were
based on traditional surgery using an operation microscope,
without the use of other tools, such as intraoperative blood
sampling of hormones, intraoperative use of MRI, neuro-
navigation or the additional use of an endoscope. If earlier
reports estimated the remission percentage to be too high,
a publication year-dependent decrease in recurrence
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76 Pituitary (2012) 15:71–83
123percentage and rate would have been expected. Indeed, the
review demonstrated a very moderate decrease in recur-
rence rate over the years, which could also be explained by
improved surgical techniques, increased experience of
neurosurgeons and the limitation of performance of pitui-
tary operations to dedicated surgeons. Furthermore, a very
weak correlation between remission and recurrence per-
centage was found, explaining only 3% of variability,
indicating that remission and recurrence are largely inde-
pendent phenomena. These observations, therefore, indi-
cate that remission rates reported in earlier publications are
not greatly inﬂuenced by less sensitive hormone assays in
use at that time.
One might suppose that a longer follow-up period will
lead to a higher recurrence rate. We investigated this
hypothesis, which was only possible in studies which
reported details on the time of recurrence after surgery, or
gave sufﬁcient data to calculate these data. Fortunately, the
percentage of studies of the 4 tumor types reporting these
details was comparable, and lying between 70 and 77%.
For a meaningful comparison between studies, the time
period was divided into bins of less than 1 year, between 1
and 5 years, between 6 and 10 years, and longer than
10 years. With the limitation that the majority of studies
were shorter than 10 years, the incidence of recurrence
peaked between 1 and 5 years, and not later. It is not
unreasonable to assume that adenoma recurrences originate
from tiny postoperative tumor remnants, with insufﬁcient
hormone secretion (or size) to affect biochemical tests or
detection with high-resolution MRI. Apparently, the
growth rates of these recurrent tumors are comparable,
although recurrence of functional tumors is no guarantee
that they can be detected by MRI or high resolution CT
scanning.
The clinical factors of age, gender, tumor size and
invasion had no predictive value in most studies, inde-
pendently of the tumor type. However, there is no agree-
ment whether silent corticotrope adenomas have a greater
growth potential than NFA tumors. This matter is of some
importance, since prophylactic postoperative irradiation
has been advocated for this type of adenoma. However, our
review indicates that this issue is still unsettled [154].
Particularly, regarding acromegaly and prolactinoma one
might expect that a normalized TRH test (normalization of
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Fig. 10 Prognostic factors of tumor recurrence. The horizontal bars
represent the number of studies reporting signiﬁcant associations
(black bars) or the absence of a statistically validated association
(gray bars). The reported factors are listed vertically for each
adenoma type. The number of studies not reporting clinical details on
recurrences is also indicated in the ﬁgure. The numbers at the end of
the bars reﬂect the total number of recurrences of that particular risk
factor and the total years at risk for the group
Pituitary (2012) 15:71–83 77
123a paradoxical GH increase in acromegaly and stimulatory
PRL in prolactinoma) would indicate permanent cure.
Indeed, in prolactinoma this was found in 3 studies, but not
in another study. A comparable situation was found in
acromegaly. A paradoxical TRH test in acromegaly is
considered as non-diagnostic and thus clinically not useful,
because it can be also present in other conditions, such as
in children, anorexia nervosa, and serious liver disease
[155]. Interestingly, acromegalic patients with a paradoxi-
cal response of GH to TRH express the TRH receptor in the
adenoma, while TRH-negative patients do not [156],
establishing the pathophysiological basis for this response.
In a selected series of acromegalic patients who had a
normal postoperative GH suppression (although differing
in magnitude) and a normalized TRH test, only one
recurrence was noted after a 14.3 years [160]. Others also
found the test useful [157] but not all [158, 159]. In our
experience, if an abnormal TRH test is the only biochem-
ical abnormality observed, it may take a long time before a
relapse becomes clinically obvious, thus requiring long-
term observations [160]. The low number of reports in
Cushing’s disease and acromegaly, relating outcome of
hormone suppression tests with recurrence. renders the
usefulness of this parameter doubtful at this time, and
careful studies, such as initiated in acromegaly by Freda
are required to establish its value [148].
The most interesting predictor of recurrence was a low
postoperative basal hormone concentration for functioning
adenomas, and not dynamic tests, although these were not
systematically investigated in most studies. Depending on
the sensitivity and speciﬁcity of the assay, a low hormone
concentration indicates no tumor remnant or a residual
tumor mass which does not lead to clinical signiﬁcant
growth. Whether this latter hypothesis is correct can only
be ascertained when more unselected studies with much
longer follow-up become available.
New pituitary deﬁciencies caused by surgery were
reported in only 60% of the publications. In the majority of
these, only basal hormone concentrations were used, rather
than dynamic tests. In addition, GH reserve was rarely
investigated with stimulation tests. Nevertheless, pituitary
function was most often disturbed in Cushing’s disease,
which can be partially explained by long-term glucocorti-
coid dependency and the commonly observed permanent
diabetes insipidus. It is also possible that more aggressive
surgery was used than in other adenomas, because of the
seriousness of the condition. In many studies details were
insufﬁcient to outline the precise distribution of newly
developed pituitary malfunction.
A new approach in pituitary surgery is the endoscopic
technique. For this review, we only found 4 studies
exclusively using the endoscopic technique and with a
sufﬁcient follow-up period for inclusion. Available studies
which compared traditional transsphenoidal microsurgery
with the endoscopic surgery indicate that the endoscopic
technique is associated with a shorter hospital stay, less
blood loss, fewer nasal complications and less frequent
diabetes insipidus. Although these ﬁndings are important,
till now no major improvement of direct postoperative
remission has been demonstrated and long-term data are
not yet available [161–163].
In summary, this analysis indicates that remission is
lowest in patients with nonfunctioning adenomas, and
recurrence is highest in patients with a prolactinoma. The
remission rate has not improved over 3 decades of publi-
cation, but there is a modest decrease in recurrences with
time. The highest incidence of tumor recurrence is between
1 and 5 years after surgery. Surgery-related hypopituita-
rism was highest in Cushing’s disease. The most important
predictor for recurrence is the postoperative basal (non-
stimulated) hormone level in functioning adenomas, while
in nonfunctioning adenomas no single convincing factor
could be identiﬁed.
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